| Name | Title | Contact Details |
|---|
Acorda Therapeutics is a publicly traded (NASDAQ: ACOR) biotechnology company whose mission is to develop therapies that restore neurological function and improve the lives of people with neurological disorders. We started our company in 1995 as a network of scientists, physicians and business people with a common belief that sharing ideas and information could lead to innovative medical advances for people with neurological disorders. We have since evolved into a commercial-stage biotechnology company, successfully developing and commercializing important therapies that advance the care of people affected by neurological conditions. We achieve our goals by: • investing in research and development • collaborating closely with the patient, medical and scientific communities • retaining employees with compassion and commitment Acorda has been voted one of the best companies to work for in New York for the past five years in a row, as a result of our dynamic environment, strong corporate culture, significant emphasis on research and development, and a robust product pipeline. We are positioned to be an industry leader, poised for exceptional growth.
Stemline Therapeutics is a clinical stage biopharmaceutical company developing oncology compounds that target cancer stem cells.
With a cancer diagnosis, early detection means better outcomes. It means hope. But when it comes to breast cancer, more than half of women have a reduced opportunity for an early, life-saving diagnosis. That`s why we`re developing Syantra DX: a blood test to detect breast cancer. It`s a revolutionary, rapid, economical approach to breast cancer screening that`s accurate regardless of the test recipient`s family history, age or tissue density.
Tute Genomics is a web-based, powerful solution for analyzing genetic sequencing data in a matter of minutes. Tute is robust, secure, professional-grade; a true web application that lives in the cloud and has the ability to analyze and annotate entire human genomes in a rapid and cost-effective way. What makes Tute stand out above the rest? Tute is built on ANNOVAR, the gold-standard in whole genome interpretation with already over 400 scientific citations. Tute pulls in 125+ annotation types, databases, and scores; more than any other analyses software. Tute can use your genome variant data in a variety of common formats (VCF, CG masterVar, and more) and uses proprietary machine-learning algorithms to rank each variant. For each genetic variant, Tute presents a human-readable annotation with links to external supporting evidence. Tute supports disease gene finding, biomarker discovery, pharmacogenetics and more.
ImmusanT, Inc is a biotechnology company focused on developing a treatment, and a set of diagnostic and monitoring tools to manage patients with Celiac disease.